As a group consisting of both manufacturers and suppliers from around the world, our interest in the global pharmaceutical industry is a practical one – where (and how) do we source the chemicals required to produce the world’s pharma? The global pharmaceutical industry is complex to say the least, development, and manufacturing spanning continents. While many consumers may not think twice about where their medications come from, understanding the geography of drug production is just one aspect of what we do everyday.
Asia:
India and China have both emerged as dominant forces in pharmaceutical manufacturing, particularly for generic drugs and active pharmaceutical ingredients (APIs). Between the two countries, roughly 60% of the global APIs are produced here.
- India is often referred to as the “pharmacy of the world,” producing approximately 20% of the global supply of generic medicines. Indian pharmaceutical exports reach over 200 countries and territories.
- China manufactures an estimated 40% of the world’s APIs—the biologically active components that make medications work. This includes essential ingredients for antibiotics, vitamins, and pain medications.
North America:
The United States remains a leader in pharmaceutical research, development, and the production of innovative, patented drugs. Companies like Pfizer, Johnson & Johnson, and Merck & Co. maintain significant manufacturing operations domestically, though they also operate facilities worldwide.
Europe:
Europe has a rich history in pharmaceutical development and remains home to some of the world’s most influential drug companies.
Switzerland
Despite its small size, Switzerland is host to two very large pharmaceutical companies:
Novartis
- One of the largest pharmaceutical companies globally
- Specializes in innovative medicines, generics (through Sandoz), and eye care
- Operates manufacturing facilities across Europe, Asia, and the Americas
- Revenue exceeds $50 billion annually
Roche (Basel)
- A world leader in oncology and diagnostics
- Pioneer in personalized healthcare
- Strong presence in biotechnology
- Operates major production facilities in Switzerland, Germany, and the United States
Germany:
Bayer
- A diversified life sciences company with a rich history dating back to 1863
- Known for products ranging from aspirin to advanced cancer treatments
- Major production sites throughout Germany and globally
- Strong focus on crop science alongside pharmaceuticals
Boehringer Ingelheim
- One of the world’s largest privately-owned pharmaceutical companies
- Specializes in respiratory diseases, cardiovascular conditions, and animal health
- Significant manufacturing presence in Germany and across Europe
United Kingdom:
GlaxoSmithKline (GSK)
- One of the world’s largest pharmaceutical companies
- Strong presence in vaccines, respiratory medicines, and consumer healthcare
- Major manufacturing sites in the UK, Belgium, and worldwide
AstraZeneca
- Roots in Sweden and UK
- Gained global recognition during COVID-19 for its vaccine partnership with Oxford University
- Focus areas include oncology, cardiovascular, and respiratory diseases
- Significant production facilities across Europe, including Sweden and the UK
France:
Sanofi
- One of the world’s largest pharmaceutical companies by prescription sales
- Global leader in vaccines through Sanofi Pasteur
- Strong presence in diabetes care, rare diseases, and immunology
- Extensive manufacturing network across France and globally
Denmark:
Novo Nordisk
- The world leader in diabetes care
- Controls approximately 30% of the global insulin market
- Recently gained attention for GLP-1 medications like Ozempic and Wegovy
- Maintains significant production in Denmark, with expanding facilities worldwide
Ireland deserves special mention as it has become a major hub for pharmaceutical manufacturing, hosting facilities for 9 of the world’s top 10 pharma companies. Favourable tax policies and a skilled workforce have attracted billions in investment.
Challenges and Trends
Supply Chain Vulnerabilities
The COVID-19 pandemic exposed significant vulnerabilities in global pharmaceutical supply chains, particularly the heavy reliance on Asian API manufacturing. This has prompted:
- European initiatives to reshore critical medicine production
- Increased investment in domestic manufacturing capabilities
- Regulatory pushes for supply chain transparency
European Competitiveness Concerns
European pharmaceutical leaders have raised concerns about maintaining competitiveness against American and Asian rivals. Key issues include:
- Regulatory complexity across EU member states
- Pricing pressures from national healthcare systems
- Need for increased R&D investment
Sustainability Focus
European companies are increasingly focused on sustainable manufacturing:
- Reducing carbon footprints
- Minimizing water usage
- Implementing circular economy principles
Conclusion
While Asian companies dominates pharmaceutical manufacturing in terms of volume – particularly for generics and APIs – Europe has become synonymous with innovation and high-value IPs. Companies like Novartis, Roche, Sanofi, and Novo Nordisk continue to drive global healthcare innovation while maintaining significant manufacturing operations on the continent.
The future is likely to see continued growth of global supply chains alongside strategic repatriation of critical production. European companies, with their strong R&D capabilities and emphasis on quality, are well-positioned to navigate this evolving landscape through ongoing investment and long-term strategy.